Atypical Lobular Hyperplasia
Understand Atypical Lobular Hyperplasia (ALH), also known as Lobular Neoplasia. This page provides information on ALH diagnosis, clinical documentation best practices, and relevant medical coding terms for healthcare professionals. Learn about the significance of ALH, its relationship to lobular carcinoma in situ, and appropriate management strategies. Find resources for accurate and efficient healthcare documentation and coding related to ALH.
Abnormal but noncancerous breast cells in the milk-producing lobules. Increased breast cancer risk.
Usually no symptoms. May be found incidentally on biopsy.
Breast biopsy for other findings, like calcifications or palpable abnormalities.
ICD-10 Code Families
Complete code families applicable to N60.B9
When to use each related code
| Description | When to use |
|---|---|
| Increased abnormal cells in breast lobules, slightly increased risk of cancer. | ALH seen on breast biopsy, no other findings suggestive of invasive or in situ cancer. |
| Abnormal cells in breast ducts, not yet invasive cancer, but increased risk. | DCIS diagnosed by breast biopsy, clearly defined extent, no evidence of invasion. |
| Group of abnormal cells within breast lobules, higher risk of cancer than ALH. | LCIS identified on biopsy, to distinguish from other lobular changes, discuss risk implications. |
Best-practice checklist
- ✓ALH/Lobular Neoplasia: Document mammogram findings.
- ✓Atypical Lobular Hyperplasia: Specify location and size.
- ✓ALH diagnosis: Include biopsy results and pathology report.
- ✓Lobular Neoplasia: Note family history of breast cancer.
- ✓Atypical Lobular Hyperplasia: Assess risk factors and management plan.
Common pitfalls to avoid
Missing or incorrect laterality (right, left, bilateral) for ALH can impact reimbursement and data accuracy. Important for breast cancer staging.
ALH may be confused with Lobular Carcinoma In Situ (LCIS). Accurate coding distinguishes risk level and guides treatment decisions.
If atypia is present, it should be documented and coded specifically, as it impacts management and prognosis. Avoid unspecified codes.
Best-practice tips
- 01ICD-10 N60.89, SNOMED CT 224825009: Accurate ALH/LN documentation
- 02Timely follow-up, close monitoring crucial for ALH/LN patients
- 03Core needle biopsy preferred for ALH/LN diagnosis confirmation
- 04Surgical excision for ALH/LN if high-risk features are present
- 05Multidisciplinary review: radiology, pathology for ALH/LN cases
Step-by-step checklist
- 1
Confirm diagnosis via core needle biopsy or excisional biopsy.
- 2
Document ALH subtype: classic, pleomorphic, or apocrine.
- 3
Assess family history of breast cancer and lobular carcinoma in situ.
- 4
Evaluate risk factors: age, hormone therapy use, reproductive history.
Ready-to-paste narrative
Patient presents with atypical lobular hyperplasia (ALH), also known as lobular neoplasia, diagnosed on core needle biopsy of the right breast. The patient reported no palpable breast lumps or skin changes. Mammography revealed an area of architectural distortion in the upper outer quadrant of the right breast, prompting biopsy. Ultrasound demonstrated a hypoechoic, irregular lesion correlating with the mammographic finding. Histopathological examination revealed atypical lobular hyperplasia, characterized by proliferation of small, monomorphic cells within the lobules, distending but not destroying the underlying lobule architecture. Immunohistochemical stains were performed and are pending. The diagnosis of atypical lobular hyperplasia signifies an increased risk of developing invasive lobular carcinoma. Differential diagnoses included fibroadenoma, sclerosing adenosis, and lobular carcinoma in situ (LCIS). Following discussion of management options including close surveillance, chemoprevention, and surgical excision, the patient elected to proceed with excisional biopsy for definitive diagnosis and risk reduction. The procedure is scheduled, and post-operative recommendations will be provided. This case highlights the importance of breast cancer screening and appropriate follow-up for high-risk breast lesions. ICD-10 code D05.11 will be utilized for atypical lobular hyperplasia of the right breast. CPT codes for the biopsy and excision will be determined based on the operative report. Continued monitoring and follow-up are recommended to assess for any changes or progression of the condition.
Common questions and answers
What is the clinical significance of Atypical Lobular Hyperplasia (ALH) and its management in patients with breast biopsies?+
Atypical Lobular Hyperplasia (ALH), also known as Lobular Neoplasia, is a non-invasive breast lesion considered a risk indicator for developing invasive lobular carcinoma (ILC) in either breast. While ALH itself isn't cancerous, its presence significantly increases breast cancer risk compared to the general population. Management typically involves close surveillance with regular mammograms and breast MRIs, along with consideration of risk-reducing medications like tamoxifen or raloxifene. The upgrade rate to invasive cancer upon surgical excision can range from 11-22%, highlighting the importance of discussing surgical excision biopsy for complete assessment. Consider implementing a personalized risk-benefit discussion with patients based on family history, age, and other risk factors. Explore how S10.AI can help assess and manage ALH cases effectively.
How can I differentiate Atypical Lobular Hyperplasia (ALH) from Lobular Carcinoma In Situ (LCIS) on breast biopsy and what are the appropriate next steps for each diagnosis?+
Differentiating Atypical Lobular Hyperplasia (ALH) and Lobular Carcinoma In Situ (LCIS) on core needle biopsy can be challenging, as both involve distension of lobules by loosely cohesive, discohesive cells with small, uniform nuclei. However, ALH demonstrates less complete filling of the lobules and may not involve all acini within a lobule, whereas LCIS typically involves complete or near-complete filling. Due to the potential for underestimation of LCIS on core biopsy, surgical excision is often recommended for a definitive diagnosis, particularly for ALH with extensive involvement or if the distinction between ALH and LCIS is uncertain. Learn more about S10.AI's potential in improving the accuracy of these diagnoses and streamlining pathology workflows.
What are the long-term surveillance recommendations for patients diagnosed with Atypical Lobular Hyperplasia (ALH) and are there any chemoprevention strategies to consider?+
Patients diagnosed with Atypical Lobular Hyperplasia (ALH) require diligent long-term surveillance due to the increased risk of developing both invasive lobular carcinoma (ILC) and invasive ductal carcinoma (IDC). Surveillance strategies generally include annual or biennial mammograms, sometimes supplemented with breast MRI, especially in high-risk patients. Chemoprevention with tamoxifen or raloxifene can be considered to reduce breast cancer risk, but the decision should be individualized based on the patient's overall risk profile, including age, family history, and potential side effects. Explore how S10.AI can assist in creating personalized surveillance plans and informing chemoprevention decisions in ALH cases.
Clinical accuracy: This information is provided for documentation and coding guidance and should not replace professional medical judgment.
Coding standard: ICD-10-CM, current FY guidelines.